Cargando…

Downregulation of CXXC Finger Protein 4 Leads to a Tamoxifen-resistant Phenotype in Breast Cancer Cells Through Activation of the Wnt/β-catenin Pathway

Tamoxifen is a successful endocrine therapy drug for estrogen receptor–positive (ER+) breast cancer. However, resistance to tamoxifen compromises the efficacy of endocrine treatment. In the present study, we identified potential tamoxifen resistance–related gene markers and investigated their mechan...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Yijie, Wang, Zhu, Luo, Chuanxu, Wang, Yu, Wang, Yanping, Zhong, Xiaorong, Zheng, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948370/
https://www.ncbi.nlm.nih.gov/pubmed/31911277
http://dx.doi.org/10.1016/j.tranon.2019.12.005
_version_ 1783485733349097472
author Fu, Yijie
Wang, Zhu
Luo, Chuanxu
Wang, Yu
Wang, Yanping
Zhong, Xiaorong
Zheng, Hong
author_facet Fu, Yijie
Wang, Zhu
Luo, Chuanxu
Wang, Yu
Wang, Yanping
Zhong, Xiaorong
Zheng, Hong
author_sort Fu, Yijie
collection PubMed
description Tamoxifen is a successful endocrine therapy drug for estrogen receptor–positive (ER+) breast cancer. However, resistance to tamoxifen compromises the efficacy of endocrine treatment. In the present study, we identified potential tamoxifen resistance–related gene markers and investigated their mechanistic details. First, we established two ER + breast cancer cell lines resistant to tamoxifen, named MCF-7/TMR and BT474/TMR. Gene expression profiling showed that CXXC finger protein 4 (CXXC4) expression is lower in MCF-7/TMR cells than in MCF-7 cells. Furthermore, CXXC4 mRNA and protein expression are lower in the resistant cell lines than in the corresponding parental cell lines. We also investigated the correlation between CXXC4 and endocrine resistance in ER + breast cancer cells. CXXC4 knockdown accelerates cell proliferation in vitro and in vivo and renders breast cancer cells insensitive to tamoxifen, whereas CXXC4 overexpression inhibits cancer cell growth and increases tamoxifen sensitivity of resistant cells. In addition, we demonstrated that CXXC4 inhibits Wnt/β-catenin signaling in cancer cells by modulating the phosphorylation of GSK-3β, influencing the integrity of the β-catenin degradation complex. Silencing the CXXC4 gene upregulates expression of cyclinD1 and c-myc (the downstream targets of Wnt signaling) and promotes cell cycle progression. Conversely, ectopic expression of CXXC4 downregulates the expression of these proteins and arrests the cell cycle in the G0/G1 phase. Finally, the small-molecule inhibitor XAV939 suppresses Wnt signaling and sensitizes resistant cells to tamoxifen. These results indicate that components of Wnt pathway that are early in response to tamoxifen could be involved as an intrinsic factor of the transition to endocrine resistance, and inhibition of Wnt signaling may be an effective therapeutic strategy to overcome tamoxifen resistance.
format Online
Article
Text
id pubmed-6948370
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-69483702020-01-09 Downregulation of CXXC Finger Protein 4 Leads to a Tamoxifen-resistant Phenotype in Breast Cancer Cells Through Activation of the Wnt/β-catenin Pathway Fu, Yijie Wang, Zhu Luo, Chuanxu Wang, Yu Wang, Yanping Zhong, Xiaorong Zheng, Hong Transl Oncol Original article Tamoxifen is a successful endocrine therapy drug for estrogen receptor–positive (ER+) breast cancer. However, resistance to tamoxifen compromises the efficacy of endocrine treatment. In the present study, we identified potential tamoxifen resistance–related gene markers and investigated their mechanistic details. First, we established two ER + breast cancer cell lines resistant to tamoxifen, named MCF-7/TMR and BT474/TMR. Gene expression profiling showed that CXXC finger protein 4 (CXXC4) expression is lower in MCF-7/TMR cells than in MCF-7 cells. Furthermore, CXXC4 mRNA and protein expression are lower in the resistant cell lines than in the corresponding parental cell lines. We also investigated the correlation between CXXC4 and endocrine resistance in ER + breast cancer cells. CXXC4 knockdown accelerates cell proliferation in vitro and in vivo and renders breast cancer cells insensitive to tamoxifen, whereas CXXC4 overexpression inhibits cancer cell growth and increases tamoxifen sensitivity of resistant cells. In addition, we demonstrated that CXXC4 inhibits Wnt/β-catenin signaling in cancer cells by modulating the phosphorylation of GSK-3β, influencing the integrity of the β-catenin degradation complex. Silencing the CXXC4 gene upregulates expression of cyclinD1 and c-myc (the downstream targets of Wnt signaling) and promotes cell cycle progression. Conversely, ectopic expression of CXXC4 downregulates the expression of these proteins and arrests the cell cycle in the G0/G1 phase. Finally, the small-molecule inhibitor XAV939 suppresses Wnt signaling and sensitizes resistant cells to tamoxifen. These results indicate that components of Wnt pathway that are early in response to tamoxifen could be involved as an intrinsic factor of the transition to endocrine resistance, and inhibition of Wnt signaling may be an effective therapeutic strategy to overcome tamoxifen resistance. Neoplasia Press 2020-01-03 /pmc/articles/PMC6948370/ /pubmed/31911277 http://dx.doi.org/10.1016/j.tranon.2019.12.005 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original article
Fu, Yijie
Wang, Zhu
Luo, Chuanxu
Wang, Yu
Wang, Yanping
Zhong, Xiaorong
Zheng, Hong
Downregulation of CXXC Finger Protein 4 Leads to a Tamoxifen-resistant Phenotype in Breast Cancer Cells Through Activation of the Wnt/β-catenin Pathway
title Downregulation of CXXC Finger Protein 4 Leads to a Tamoxifen-resistant Phenotype in Breast Cancer Cells Through Activation of the Wnt/β-catenin Pathway
title_full Downregulation of CXXC Finger Protein 4 Leads to a Tamoxifen-resistant Phenotype in Breast Cancer Cells Through Activation of the Wnt/β-catenin Pathway
title_fullStr Downregulation of CXXC Finger Protein 4 Leads to a Tamoxifen-resistant Phenotype in Breast Cancer Cells Through Activation of the Wnt/β-catenin Pathway
title_full_unstemmed Downregulation of CXXC Finger Protein 4 Leads to a Tamoxifen-resistant Phenotype in Breast Cancer Cells Through Activation of the Wnt/β-catenin Pathway
title_short Downregulation of CXXC Finger Protein 4 Leads to a Tamoxifen-resistant Phenotype in Breast Cancer Cells Through Activation of the Wnt/β-catenin Pathway
title_sort downregulation of cxxc finger protein 4 leads to a tamoxifen-resistant phenotype in breast cancer cells through activation of the wnt/β-catenin pathway
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948370/
https://www.ncbi.nlm.nih.gov/pubmed/31911277
http://dx.doi.org/10.1016/j.tranon.2019.12.005
work_keys_str_mv AT fuyijie downregulationofcxxcfingerprotein4leadstoatamoxifenresistantphenotypeinbreastcancercellsthroughactivationofthewntbcateninpathway
AT wangzhu downregulationofcxxcfingerprotein4leadstoatamoxifenresistantphenotypeinbreastcancercellsthroughactivationofthewntbcateninpathway
AT luochuanxu downregulationofcxxcfingerprotein4leadstoatamoxifenresistantphenotypeinbreastcancercellsthroughactivationofthewntbcateninpathway
AT wangyu downregulationofcxxcfingerprotein4leadstoatamoxifenresistantphenotypeinbreastcancercellsthroughactivationofthewntbcateninpathway
AT wangyanping downregulationofcxxcfingerprotein4leadstoatamoxifenresistantphenotypeinbreastcancercellsthroughactivationofthewntbcateninpathway
AT zhongxiaorong downregulationofcxxcfingerprotein4leadstoatamoxifenresistantphenotypeinbreastcancercellsthroughactivationofthewntbcateninpathway
AT zhenghong downregulationofcxxcfingerprotein4leadstoatamoxifenresistantphenotypeinbreastcancercellsthroughactivationofthewntbcateninpathway